SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-002348
Filing Date
2023-11-13
Accepted
2023-11-13 08:15:58
Documents
75
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tmb-20230930x10q.htm   iXBRL 10-Q 1719261
2 EX-31.1 tmb-20230930xex31d1.htm EX-31.1 14171
3 EX-32.1 tmb-20230930xex32d1.htm EX-32.1 8514
4 GRAPHIC tmb-20230930x10q001.jpg GRAPHIC 47635
  Complete submission text file 0001410578-23-002348.txt   7748022

Data Files

Seq Description Document Type Size
5 EX-101.SCH tmb-20230930.xsd EX-101.SCH 56634
6 EX-101.CAL tmb-20230930_cal.xml EX-101.CAL 68473
7 EX-101.DEF tmb-20230930_def.xml EX-101.DEF 254292
8 EX-101.LAB tmb-20230930_lab.xml EX-101.LAB 494710
9 EX-101.PRE tmb-20230930_pre.xml EX-101.PRE 375116
69 EXTRACTED XBRL INSTANCE DOCUMENT tmb-20230930x10q_htm.xml XML 1293889
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12584 | Film No.: 231395320
SIC: 2834 Pharmaceutical Preparations